|
- New England Journal of Medicine
The New England Journal of Medicine publishes high-quality medical research, reviews, and opinions to advance medical science and improve patient care
- The New England Journal of Medicine | Research Review Articles on . . .
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of
- Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer
- Recently Published | The New England Journal of Medicine
Explore this issue of The New England Journal of Medicine (Vol 0 No 0)
- Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes
Zimislecel is an allogeneic stem cell–derived islet-cell therapy Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed We conducted a phase 1–2 study of
- Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise program
- A New Perspective Series - The New England Journal of Medicine
As health systems confront the social, economic, and political drivers underlying worsening U S population health, a new Perspective series examines the extent to which the business of health care
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight . . .
Semaglutide at a dose of 2 4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2 4 mg has shown promising results in early-phase trials; the efficacy of the
|
|
|